OBJECTIVES:  Type 2 diabetes mellitus (T2DM) is a chronic disorder and requires lifelong treatment. It poses significant burden on healthcare costs. This study was carried out with an aim to assess the efficacy and safety of once weekly dulaglutide for patients with T2DM. METHODS:  An extensive literature search was done in Pubmed, Cochrane central register and other databases for clinical trial (CTs) comparing the efficacy and safety of dulaglutide with other oral hypoglycaemic agents or placebo in the treatment of T2DM from inception to 14^th April, 2016 by two independent reviewers. A total of 12 RCTs including total of 8870 patients comparing dulaglutide (4598 patients) to Control (4272 patients) are pooled in the present analysis. Quality of included studies was determined by Cochrane risk of bias tool. Cochrane Q (p <0.05) or I test (>50%) was used to assess the heterogeneity. Subgroup analysis was performed. All analyses were performed using Comprehensive Meta-analysis. RESULTS:  Fixed effect model was used for pooled analysis as no significant heterogeneity was observed. The pooled Weighted Mean Difference (WMD = -0.40, 95% CI -0.43 to -0.36, p = 0.00) shows, dulaglutide significantly lowered HbA1c over control (placebo, metformin, and liraglutide) as well as fasting plasma glucose (FPG) and body weight (WMD = -0.18, 95% CI -0.22 to -0.12, and -0.24, 95% CI -0.3 to -0.2, p = 0.00, respectively). Moreover, Dulaglutide significantly increasing 55% and 33% to achieve HbA1c <7% and <6.5% respectively and significantly decreasing the incidence of hypoglycemia (12%) as compared to control. CONCLUSIONS:  The finding of our study reveals the beneficial effects of dulaglutide with respect to HbA1c, FPG and weight reduction in comparison to other oral hypoglycaemic agents. Dulaglutide also demonstrate satisfactory safety profile.